Top

Published in:

23-07-2022 | Alopecia | Original Article

Factors influencing scalp cooling discussions and use at a large academic institution: a single-center retrospective review

Authors: Taylor Novice, Madison Novice, David Portney, Joshua Goyert, N. Lynn Henry, Jacqueline S. Jeruss, Monika L. Burness

Published in: Supportive Care in Cancer | Issue 10/2022

Abstract

Purpose

Chemotherapy-induced alopecia (CIA) is a stigmatizing and psychologically devasting side effect of cancer treatment. Scalp cooling therapy (SCT) is the most effective method to reduce CIA, yet it is underutilized. We investigated factors that may impact scalp cooling discussion and use.

Methods

We performed a retrospective review of cancer patients from 2000 to 2019 who had documentation of SCT discussion in the electronic medical record. The University of Michigan Rogel Cancer Center registry was used to identify the total number of cancer patients eligible for SCT during 2015–2019. Chi-square tests were used for outcome and patient characteristic comparisons (p < 0.05).

Results

From 2000 to 2019, 194 patients had documentation of SCT discussion. Of those, 72 (43.6%) used SCT, 93 (47.9%) did not use SCT, and the remaining 29 (17.8%) had unknown SCT use. A total of 5615 cancer patients were eligible for SCT from 2015 to 2019. As compared to those who did not have documented SCT discussions, patients who had documentation of SCT discussions in that period (n = 161, 3.0%) were more likely to be female, have breast cancer, be less than 45 years old, and live in a zip code with average income > US $100,000 (all p < 0.0001). Between 2015 and 2019, 57 patients (1.02%) used SCT. On univariate analysis, patient-initiated conversation about SCT (p = 0.01) and age less than 65 (p = 0.03) were significantly associated with decision to use SCT.

Conclusion

There were distinctions in the types of patients who have documented discussions about SCT. Improving patient knowledge about the availability of SCT and increasing access to this technology for all eligible cancer patients may enable more patients to achieve improved quality of life by reducing or preventing CIA.

Hershman DL (2017) Scalp cooling to prevent chemotherapy-induced alopecia: the time has come. JAMA 317(6):587–588. https://doi.org/10.1001/jama.2016.21039 (United States)CrossRefPubMed

Freites-Martinez A et al (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199–1213. https://doi.org/10.1016/j.jaad.2018.03.056CrossRefPubMed

Singer S, Tkachenko E, Sharma P, Nelson C, Mostaghimi A, LeBoeuf NR (2020) Geographic disparities in access to scalp cooling for the prevention of chemotherapy-induced alopecia in the United States. J Am Acad Dermatol. https://doi.org/10.1016/j.jaad.2020.06.073CrossRefPubMedPubMedCentral

The Rapunzel Project: Dignicap, Paxman, and Biomedical Freezer Locations, 2021

Novice M, Novice T, Henry NL, Johnson K, Jeruss JS, Kidwell KM, Burness ML (2022) Identifying barriers and facilitators to scalp cooling therapy through a national survey of the awareness, practice patterns, and attitudes of oncologists. JCO Oncol Pract 18(2):e225-e234

Peerbooms M, van den Hurk CJ, Breed WP (2015) Familiarity, opinions, experiences and knowledge about scalp cooling: a Dutch survey among breast cancer patients and oncological professionals. Asia-Pacific J Oncol Nurs 2(1):35–41. https://doi.org/10.4103/2347-5625.152404CrossRef

Shaw JM et al (2018) Barriers and enablers to implementing scalp cooling in Australia: a qualitative study of health professionals’ attitudes to and experience with scalp cooling. Support Care Cancer 26(1):305–312. https://doi.org/10.1007/s00520-017-3849-7CrossRefPubMed

Shaw J et al (2016) Scalp cooling: a qualitative study to assess the perceptions and experiences of Australian patients with breast cancer. Support Care Cancer 24(9):3813–3820. https://doi.org/10.1007/s00520-016-3206-2CrossRefPubMed

Williams NO et al (2021) Real-world data on usage of scalp cooling for chemotherapy associated alopecia in the United States. J Clin Oncol 39(15_suppl):e18739–e18739. https://doi.org/10.1200/JCO.2021.39.15_suppl.e18739CrossRef

10.

Nangia J (2018) Quality of life matters: it is time to integrate scalp cooling in routine clinical practice. J Oncol Pract 14(3):157–158. https://doi.org/10.1200/JOP.18.00033 (United States)CrossRefPubMed

11.

Rugo HS (2017) Real-world use of scalp cooling to reduce chemotherapy-related hair loss. Clin Adv Hematol Oncol : H&O 15(11):828–831 (United States)

12.

Hanauer DA, Mei Q, Law J, Khanna R, Zheng K (2015) Supporting information retrieval from electronic health records: a report of University of Michigan’s nine-year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform 55:290–300. https://doi.org/10.1016/j.jbi.2015.05.003CrossRefPubMedPubMedCentral

13.

Van Den Hurk CJ, Peerbooms M, Van De Poll-Franse LV, Nortier JW, Coebergh JWW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol (Madr) 51(4):497–504. https://doi.org/10.3109/0284186X.2012.658966CrossRef

14.

Rugo HS et al (2017) Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA - J Am Med Assoc 317(6):606–614. https://doi.org/10.1001/jama.2016.21038CrossRef

15.

Nangia J et al (2017) Effect of a scalp cooling device on alopecia inwomen undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA - J Am Med Assoc 317(6):596–605. https://doi.org/10.1001/jama.2016.20939CrossRef

16.

Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S (2008) Have men been overlooked? A comparison of young men and women’s experiences of chemotherapy-induced alopecia. Psychooncology 17(6):577–583. https://doi.org/10.1002/pon.1272CrossRefPubMed

17.

P. USA (2018) FDA clearance for expanded indication - Paxman USA Scalp Cooling. https://www.paxmanusa.com/news/3016

18.

Commissioner O of the FDA clears expanded use of cooling cap to reduce hair loss during chemotherapy, 2020

19.

van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, Nortier JW, Coebergh JWW, Breed WP (2012) Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol 51(4):497–504. https://doi.org/10.3109/0284186X.2012.658966CrossRefPubMed

20.

T. R. Project (n.d.) The Rapunzel Project. http://www.rapunzelproject.org

21.

The AMA issues CPT® category III codes for mechanical scalp cooling, 2021. https://paxmanscalpcooling.com/the-ama-issues-cpt-category-iii-codes-for-mechanical-scalp-cooling/#:~:text=The new CPT® Category,once per chemotherapy treatment period)

22.

Bedard T (2022) Oncology coding update. Oncology Issues 37.1(2022):8–19

23.

Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME (2018) Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 167(1):117–122. https://doi.org/10.1007/s10549-017-4506-zCrossRefPubMed

24.

Vu JV, Llarena NC, Estevez SL, Moravek MB, Jeruss JS (2017) Oncofertility program implementation increases access to fertility preservation options and assisted reproductive procedures for breast cancer patients. J Surg Oncol 115(2):116–121. https://doi.org/10.1002/jso.24418CrossRefPubMed

Title: Factors influencing scalp cooling discussions and use at a large academic institution: a single-center retrospective review
Authors: Taylor Novice
Madison Novice
David Portney
Joshua Goyert
N. Lynn Henry
Jacqueline S. Jeruss
Monika L. Burness
Publication date: 23-07-2022
Publisher: Springer Berlin Heidelberg
Keywords: Alopecia
Breast Cancer
Breast Cancer
Cytostatic Therapy
Published in: Supportive Care in Cancer / Issue 10/2022
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-022-07285-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2022

Understanding the experiences of older caregivers of patients with lung cancer during palliative chemotherapy in China: a qualitative study

Effectiveness of psychoeducation intervention among women with gynecological cancer: a systematic review and meta-analysis of randomized controlled trials

Finding My Way from clinical trial to open access dissemination: comparison of uptake, adherence, and psychosocial outcomes of an online program for cancer-related distress

The clinical application value of phase angle of six parts in nutritional evaluation of tumor patients

Prevalence of constipation in patients undergoing chemotherapy and the effect of constipation on quality of life

Confounding factors in the assessment of oral mucositis in head and neck cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer